Dermatological Manifestation in Coronavirus Disease 2019 Patients in Iraq


  • Anfal L. Al-Harbawi Department of Medicine, Dermatology Section, Arab Board of Dermatology (FABHS Dermatology and Venereology), Mosul University, Mosul, Iraq
  • Qasim S. Al Chalabi Department of Medicine, Dermatology Section, Arab Board of Dermatology (FABHS Dermatology and Venereology), Mosul University, Mosul, Iraq
  • Hala N. Alsalman Department of Medicine, Dermatology Section, Iraqi Board of Dermatology (FIBMS Dermatology and Venereology), Mosul University, Mosul, Iraq
  • Mohammad S. Saeed Dermatology Section, Arab Board of Dermatology (FABHS Dermatology and Venereology), Al Sadir Teaching Hospital in Misan, Basrah, Iraq



Coronavirus disease-19, Severe acute respiratory syndrome coronavirus 2, Skin manifestation, Lesion


Background: Coronavirus disease-19 (COVID-19) is a growing pandemic around the globe that was initially discovered in Wuhan in December 2019. Despite the relatively high incidence of cutaneous manifestations in COVID-19, their role in early recognition and disease progression has not been fully investigated.

Aim of this study: To report the possible incidence of the cutaneous lesion in COVID 19 patients and to describe various cutaneous manifestations and their correlation with other clinical features in Covid-19 positive patients to facilitate diagnosis and prognostications toward this virus.

Methods: This research was conducted as a cross-sectional study. Skin lesions photography and their analysis were collected by dermatologists from 18 cities in Iraq between September 2020 to January 2021. The data were processed using statistical package SPSS version 23.

Results: A total of 3117 confirmed COVID-19 cases were included in this study. Around 268 patients developed skin lesions with age ranged between 8 to 84 years. Of these skin lesions, 46.2% developed during the illness with minority erupting during the prodromal phase, whilst 38.8% appeared after hospitalization. The most common skin lesion was in the form of urticarial 36.74% followed by herpetic lesions 28.4%, maculopapular rash 11.74% and the remainder being candidiasis, oral thrush, chilblains, and other skin conditions. The most affected area was the torso (46%) followed by limbs, face, fingers, and toes.

Conclusion: This study demonstrated the high incidence rate of dermatological lesions in different phases of COVID-19 with urticarial rash being the most frequent clinical pattern.



Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Potekaev NN, Zhukova OV, Protsenko DN, Demina OM, Khlystova EA, Bogin V. Clinical characteristics of dermatologic manifestations of COVID‐19 infection: Case series of 15 patients, review of literature, and proposed etiological classification. Int J Dermatol. 2020;59(8):1000-9. PMid:32621287

Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P4, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-7. PMid:32348545

Guertler A, Moellhoff N, Schenck TL, Hagen CS, Kendziora B, Giunta RE, et al. Onset of occupational hand eczema among healthcare workers during the SARS-CoV-2 pandemic: Comparing a single surgical site with a COVID-19 intensive care unit. Contact Dermatitis. 2020;83(2):108-114. PMid:32452036

Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol. 2020;34(6):e246-7. PMid:32294259

Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

Recalcati S. Cutaneous manifestations in COVID-19: A first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-3. PMid:32215952

Young S, Fernandez AP. Skin manifestations of COVID-19. Cleve Clin J Med. 2020;2020:ccc031. PMid:32409442

Türsen Ü, Türsen B, Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther. 2020;33(4):e13476. PMid:32358890

Schulkes KJ, Van den Elzen MT, Hack EC, Otten HG, Bruijnzeel-Koomen CA, Knulst AC. Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: A retrospective study. Clin Transl Allergy. 2015;5(1):5. PMid:25664168

Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr Dermatol. 2020;37(3):435-6. PMid:32315079

Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID-19: An evidence-based review. Am J Clin Dermatol. 2020;21(5):627-39. PMid:32865778

Kaya G, Kaya A, Saurat JH. Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID- 19: Review of the literature. Dermatopathology. 2020;7(1):3-16. PMid:32608380

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. PMid:15141377

Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. J Am Acad Dermatol. 2020;83(1):e57-60. PMid:32339706




How to Cite

Al-Harbawi AL, Al Chalabi QS, Alsalman HN, Saeed MS. Dermatological Manifestation in Coronavirus Disease 2019 Patients in Iraq. Open Access Maced J Med Sci [Internet]. 2021 Oct. 10 [cited 2021 Dec. 4];9(B):1085-91. Available from: